Materiały źródłowe

• #1 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Diagnosis of prostate cancer (PCa) and adequate staging play a fundamental role for clinical and patient care. Despite major advances in biology and imaging, rectal examination and prostate-specific antigen (PSA) blood test remain the cornerstone for screening, and multiparametric magnetic resonance imaging (mpMRI) for local staging. […] Today, TRUS prostate biopsy remains the gold standard examination to confirm diagnosis in all these clinical situations. […] TRUS-guided systematic biopsy has been the standard diagnostic test for PCa since a landmark study in 1989 which showed that it was superior to digitally directed biopsy sampling of the prostate. […] Thus urologists need to improve the selection of patients requiring a biopsy and evaluate their technique to identify and hit potential aggressive lesions.

• #2 How We Diagnose Prostate Cancer | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/prostate-cancer/diagnosis

  Beginning with your first appointment at the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center, you will be matched with specialists and researchers who study genitourinary cancers exclusively. […] Finding the right pathologists and radiologists to manage your prostate cancer diagnosis is key to developing a successful treatment plan. Our radiology and pathology teams are devoted to prostate cancer, evaluating over 2,200 cases each year. […] As men age, the risk of developing prostate cancer increases. Many men will develop prostate cancer, but not all develop a harmful form of the disease. That’s why it’s important to be tested and treated as early as possible. Early diagnosis can improve your chances for successful treatment and recovery. […] These tests are most commonly used to diagnose prostate cancer:

• #3 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  Most prostate cancers are first found as a result of screening. Early prostate cancers usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. […] If prostate cancer is suspected based on results of screening tests or symptoms, tests will be needed to be sure. […] The actual diagnosis of prostate cancer can only be made with a prostate biopsy. […] The PSA blood test can be used to screen for prostate cancer in men without symptoms. It’s also one of the first tests done in men who have symptoms that might be caused by prostate cancer. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] If the results of a PSA blood test, DRE, or other tests suggest that you might have prostate cancer, you will most likely need a prostate biopsy.

• #4 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  Get answers to the most frequently asked questions about prostate cancer from Mayo Clinic urologist Mitchell Humphreys, M.D. […] Prostate cancer diagnosis often starts with an exam and a blood test. A healthcare professional might do these tests as part of prostate cancer screening. Or you might have these tests if you have prostate cancer symptoms. If these first tests detect something concerning, imaging tests can make pictures of the prostate to look for signs of cancer. To be sure whether you have prostate cancer or not, a sample of prostate cells might be removed for testing. […] Prostate cancer screening tests look for prostate cancer in people who don’t have any symptoms of the disease. Tests typically include a prostate-specific antigen blood test and a digital rectal exam. […] Most experts recommend talking with your healthcare professional about prostate cancer screening around age 50. Together you can decide whether screening is right for you. You might consider starting the discussions sooner if you’re a Black person, have a family history of prostate cancer or have other risk factors.

• #5 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Screening is testing to find cancer in people before they have symptoms. At this time, its not clear if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. […] The screening tests discussed here can be used to look for possible signs of prostate cancer. But these tests cant tell for sure if you have cancer. If the result of one of these tests is abnormal, you will probably need a prostate biopsy to know for sure if you have cancer. […] Prostate-specific antigen (PSA) is a protein made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly in semen, but a small amount is also found in the blood. […] The PSA level in blood is measured in units called nanograms per milliliter (ng/mL). The chance of having prostate cancer goes up as the PSA level goes up, but there is no set cutoff point that can tell for sure if a man does or doesnt have prostate cancer.

• #6 Diagnosis of Prostate Cancer – Prostate Cancer | UCLA Health Jonsson Comprehensive Cancer Center

  https://www.uclahealth.org/cancer/cancer-services/prostate-cancer/diagnosis-prostate-cancer

  Prostate cancer screening consists of: […] Digital rectal examination – doctor inserts a lubricated gloved finger into the rectum to check for lumps on the prostate. […] Prostate-specific antigen (PSA) blood test – a blood sample is analyzed for levels of a protein produced by the prostate that, when elevated, can indicate the presence of cancer. […] New urinary (PCA3 and MDx Select) and blood (4K score and PHI test) biomarkers are also used at times to screen for prostate cancer in men considered to be at-risk for the diagnosis. […] Early detection is key to achieving cure in men with prostate cancer. […] At UCLA, our ability to identify men at an early stage is enhanced by our cutting-edge prostate imaging program, which utilizes the most advanced MRI technology to find tumors that conventional approaches such as ultrasound can miss.

• #7 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  Get answers to the most frequently asked questions about prostate cancer from Mayo Clinic urologist Mitchell Humphreys, M.D. […] Prostate cancer diagnosis often starts with an exam and a blood test. A healthcare professional might do these tests as part of prostate cancer screening. Or you might have these tests if you have prostate cancer symptoms. If these first tests detect something concerning, imaging tests can make pictures of the prostate to look for signs of cancer. To be sure whether you have prostate cancer or not, a sample of prostate cells might be removed for testing. […] Prostate cancer screening tests look for prostate cancer in people who don’t have any symptoms of the disease. Tests typically include a prostate-specific antigen blood test and a digital rectal exam. […] Most experts recommend talking with your healthcare professional about prostate cancer screening around age 50. Together you can decide whether screening is right for you. You might consider starting the discussions sooner if you’re a Black person, have a family history of prostate cancer or have other risk factors.

• #8 Prostate-Specific Antigen (PSA) Test – NCI

  https://www.cancer.gov/types/prostate/psa-fact-sheet

  Some organizations do recommend that men who are at higher risk of prostate cancer have routine PSA testing, beginning at age 40 or 45. Those at higher risk include Black men, men with inherited variants in BRCA2 (and to a lesser extent, in BRCA1), and men whose father or brother had prostate cancer. […] The current recommendation of the United States Preventive Serves Task Force (USPSTF), which applies both to the general population and to those at increased risk due to race/ethnicity or family history, is as follows: For individuals aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one. Before making the decision, a person should discuss the potential benefits and harms of screening with their clinician and consider these in the context of their own values and preferences. PSA-based screening for prostate cancer is not recommended for individuals 70 years and older.

• #9 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a digital rectal exam, a healthcare professional inserts a gloved, lubricated finger into the rectum. The health professional feels the prostate gland for anything concerning in the texture, shape or size of the gland. […] A prostate-specific antigen test is a blood test that measures the amount of prostate-specific antigen in the blood. Prostate-specific antigen, also called PSA, is a substance that prostate cells make. Some PSA circulates in the blood. A PSA test detects the PSA in a blood sample. […] Having a high level of PSA in your blood can be a sign of prostate cancer. But many other things also can cause a high PSA level, including prostate infection and prostate enlargement. If a PSA test detects an increased level of PSA in your blood, the test is usually repeated. Your healthcare professional might recommend doing the test again in a few weeks to see if the level goes down. If the level stays high, you might need an imaging test or a biopsy procedure to look for signs of cancer.

• #10 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Screening is testing to find cancer in people before they have symptoms. At this time, its not clear if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. […] The screening tests discussed here can be used to look for possible signs of prostate cancer. But these tests cant tell for sure if you have cancer. If the result of one of these tests is abnormal, you will probably need a prostate biopsy to know for sure if you have cancer. […] Prostate-specific antigen (PSA) is a protein made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly in semen, but a small amount is also found in the blood. […] The PSA level in blood is measured in units called nanograms per milliliter (ng/mL). The chance of having prostate cancer goes up as the PSA level goes up, but there is no set cutoff point that can tell for sure if a man does or doesnt have prostate cancer.

• #11 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Most men without prostate cancer have PSA levels under 4 ng/mL of blood. When prostate cancer develops, the PSA level often goes above 4. Still, a level below 4 is not a guarantee that a man doesnt have cancer. About 15% of men with a PSA below 4 will have prostate cancer if a biopsy is done. […] Men with a PSA level between 4 and 10 (often called the borderline range) have about a 1 in 4 chance of having prostate cancer. […] If the PSA is more than 10, the chance of having prostate cancer is over 50%. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] DRE is less effective than the PSA blood test in finding prostate cancer, but it can sometimes find cancers in men with normal PSA levels. For this reason, it might be included as a part of prostate cancer screening.

• #12 Biomarkers for Prostate Cancer: From Diagnosis to Treatment

  https://www.mdpi.com/2075-4418/13/21/3350

  To address these issues, a biopsy may be suggested when two abnormal PSA levels or a palpable abnormality are present. […] In recent years, the growing understanding of the malignant biological characteristics of PCa and its molecular attributes has enabled the discovery of multiple biomarkers, which have been integrated with current diagnostic methods, risk assessments, and treatment selections. […] The specificity of using PSA as a screening tool for PCa has its limitations, especially when the PSA levels are lower than 10 µg/L. This lack of specificity results in a substantial proportion of men undergoing biopsies, either to confirm or rule out a malignancy, unnecessarily. […] To improve precision and decrease the occurrence of unnecessary or repeated biopsies, various supplementary tests such as the PHI, the 4K score, and PCA3 have been proposed.

• #13 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  PSA is, broadly speaking, an organ-specific glycoprotein secreted by the prostatic epithelium which may be elevated in a variety of conditions, both benign and malignant. Higher levels of PSA indicate a greater likelihood of prostate cancer. A PSA cut-off of 4ng/ml was originally proposed as a normal level in men aged 50-70 years. However, analysis of men with a PSA level of 4.0ng/ml in the Prostate Cancer Prevention Trial (PCPT) found 15% had clinically significant prostate cancer. Therefore, the ability to detect prostate cancer at any PSA level means that no cut-off thresholds for PSA can be used with absolute confidence. Furthermore, a single elevated PSA reading cannot be relied upon due to normal biological fluctuations. A population-based study found that 30% of men with an abnormal PSA had a return to normal PSA on their next reading. This highlights the importance of obtaining a confirmatory PSA reading a few weeks after the first reading. The unreliability of PSA means instead the urologist must take into consideration additional factors to determine if the patient should proceed to biopsy, which may include PSA derivatives.

• #14 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Screening is testing to find cancer in people before they have symptoms. At this time, its not clear if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. […] The screening tests discussed here can be used to look for possible signs of prostate cancer. But these tests cant tell for sure if you have cancer. If the result of one of these tests is abnormal, you will probably need a prostate biopsy to know for sure if you have cancer. […] Prostate-specific antigen (PSA) is a protein made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly in semen, but a small amount is also found in the blood. […] The PSA level in blood is measured in units called nanograms per milliliter (ng/mL). The chance of having prostate cancer goes up as the PSA level goes up, but there is no set cutoff point that can tell for sure if a man does or doesnt have prostate cancer.

• #15 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Most men without prostate cancer have PSA levels under 4 ng/mL of blood. When prostate cancer develops, the PSA level often goes above 4. Still, a level below 4 is not a guarantee that a man doesnt have cancer. About 15% of men with a PSA below 4 will have prostate cancer if a biopsy is done. […] Men with a PSA level between 4 and 10 (often called the borderline range) have about a 1 in 4 chance of having prostate cancer. […] If the PSA is more than 10, the chance of having prostate cancer is over 50%. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] DRE is less effective than the PSA blood test in finding prostate cancer, but it can sometimes find cancers in men with normal PSA levels. For this reason, it might be included as a part of prostate cancer screening.

• #16 Prostate-Specific Antigen (PSA) Test – NCI

  https://www.cancer.gov/types/prostate/psa-fact-sheet

  There is no single threshold that distinguishes a normal versus an abnormal PSA result. This is in part because there is no specific PSA level that means that someone has prostate cancer. However, the higher someone’s PSA level, the likelier it is that prostate cancer is present. […] If someone who has no symptoms of prostate cancer chooses to undergo prostate cancer screening and is found to have an abnormal PSA level, the doctor may recommend another PSA test in 6 to 8 weeks to confirm the original finding. If the PSA level is still elevated, the doctor may recommend continued observation with repeat PSA tests along with digital rectal exams (DREs) to watch for any changes over time. […] The potential benefit of the PSA test for prostate cancer screening is that it may help detect prostate cancer earlier, before it spreads and when it may be easier to treat, possibly reducing someone’s risk of dying from prostate cancer.

• #17 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Most men without prostate cancer have PSA levels under 4 ng/mL of blood. When prostate cancer develops, the PSA level often goes above 4. Still, a level below 4 is not a guarantee that a man doesnt have cancer. About 15% of men with a PSA below 4 will have prostate cancer if a biopsy is done. […] Men with a PSA level between 4 and 10 (often called the borderline range) have about a 1 in 4 chance of having prostate cancer. […] If the PSA is more than 10, the chance of having prostate cancer is over 50%. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] DRE is less effective than the PSA blood test in finding prostate cancer, but it can sometimes find cancers in men with normal PSA levels. For this reason, it might be included as a part of prostate cancer screening.

• #18 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  In addition to changes in PSA with age, the Olmstead county population study also demonstrated an increase in PSA with increasing prostate volume. To account for this, PSA density can be calculated as the total PSA divided by prostate volume. An increased PSA density is associated with a higher risk of prostate cancer, with a generally agreed cut off value of between 0.12-0.15 ng/ml/cc. A prospective multi-center study in patients undergoing an extended template biopsy has found PSA density to be more predictive than total PSA for detecting prostate cancer. […] Changes in PSA over time can be assessed as PSA velocity (change in PSA over time, ng/ml/year) and PSA doubling time (number of months for the PSA to increase two-fold). Whilst PSA kinetics are useful for prognostic purposes after patients have received treatment, they currently have no role in the diagnostic setting.

• #19 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Total PSA readings include the sum of all detectable forms of PSA, including PSA bound to protease inhibitors and free PSA. For reasons that are unclear, the percentage of free PSA has been demonstrated to be lower in patients with prostate cancer compared to those with benign disease. A multi-center prospective study evaluated men with a benign prostate gland on palpation and a total PSA level of 4 to 10 ng/ml. The study found the probability of prostate cancer in men aged 65 to 75 years was 55% when the free/total (f/t) PSA ratio was 0.1 and reduced to just 9% when the f/t PSA ratio was 0.25. Therefore, in these select patients with a benign prostate gland and PSA of 4 to 10 ng/ml measuring free PSA may help to avoid unnecessary imaging or biopsy; but it should be used cautiously as it can be affected by other factors including prostate volume and most patients f/t PSA ratio falls between 0.1 and 0.25.

• #20 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  In addition to changes in PSA with age, the Olmstead county population study also demonstrated an increase in PSA with increasing prostate volume. To account for this, PSA density can be calculated as the total PSA divided by prostate volume. An increased PSA density is associated with a higher risk of prostate cancer, with a generally agreed cut off value of between 0.12-0.15 ng/ml/cc. A prospective multi-center study in patients undergoing an extended template biopsy has found PSA density to be more predictive than total PSA for detecting prostate cancer. […] Changes in PSA over time can be assessed as PSA velocity (change in PSA over time, ng/ml/year) and PSA doubling time (number of months for the PSA to increase two-fold). Whilst PSA kinetics are useful for prognostic purposes after patients have received treatment, they currently have no role in the diagnostic setting.

• #21 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Total PSA readings include the sum of all detectable forms of PSA, including PSA bound to protease inhibitors and free PSA. For reasons that are unclear, the percentage of free PSA has been demonstrated to be lower in patients with prostate cancer compared to those with benign disease. A multi-center prospective study evaluated men with a benign prostate gland on palpation and a total PSA level of 4 to 10 ng/ml. The study found the probability of prostate cancer in men aged 65 to 75 years was 55% when the free/total (f/t) PSA ratio was 0.1 and reduced to just 9% when the f/t PSA ratio was 0.25. Therefore, in these select patients with a benign prostate gland and PSA of 4 to 10 ng/ml measuring free PSA may help to avoid unnecessary imaging or biopsy; but it should be used cautiously as it can be affected by other factors including prostate volume and most patients f/t PSA ratio falls between 0.1 and 0.25.

• #22 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Total PSA (tPSA) remains the cornerstone of biological test in this evolving landscape of tumor markers. […] The choice of a PSA threshold at which a clinician might recommend a biopsy remains controversial. […] PSA kinetics have emerged and may have greater specificity for clinically significant PCa. […] A novel approach to improve the clinical performance of PSA is to combine the results of three automated blood tests (tPSA, fPSA, and [-2] proPSA) using a mathematical formula termed the Phi. […] The Phi score has an AUC of 0.703 for discrimination of high-grade cancer from low-grade cancer or negative biopsies. […] PCa gene 3 (PCA3) mRNA, which is over-expressed in men with a PCa has been evaluated for guiding biopsy decisions for men with previously negative biopsies and PSA levels persistently 4 ng/mL.

• #23 Prostate Cancer Diagnosis | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/prostate/diagnosis

  A biomarker is a biological molecule found in our bodies that can tell us if something is normal or not. Biomarkers have become part of the molecular tests we use to diagnose prostate cancer. […] New biomarkers let us precisely find prostate cancer, guide treatment decisions, monitor response to treatment, and track the cancer’s growth. […] These are some of the new diagnostic tests available: […] The 4Kscore Test is a follow-up blood test given after an abnormal PSA test or DRE. It scores your risk for having aggressive prostate cancer. […] The Prostate Health Index (PHI) is a new combination of 3 blood tests. The PHI score gives information about the chances of finding cancer with a biopsy after an elevated PSA level. […] A urine test can find PCA3, a gene that is specific to prostate cancer.

• #24 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Total PSA (tPSA) remains the cornerstone of biological test in this evolving landscape of tumor markers. […] The choice of a PSA threshold at which a clinician might recommend a biopsy remains controversial. […] PSA kinetics have emerged and may have greater specificity for clinically significant PCa. […] A novel approach to improve the clinical performance of PSA is to combine the results of three automated blood tests (tPSA, fPSA, and [-2] proPSA) using a mathematical formula termed the Phi. […] The Phi score has an AUC of 0.703 for discrimination of high-grade cancer from low-grade cancer or negative biopsies. […] PCa gene 3 (PCA3) mRNA, which is over-expressed in men with a PCa has been evaluated for guiding biopsy decisions for men with previously negative biopsies and PSA levels persistently 4 ng/mL.

• #25 Prostate Cancer Diagnosis | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/prostate/diagnosis

  A biomarker is a biological molecule found in our bodies that can tell us if something is normal or not. Biomarkers have become part of the molecular tests we use to diagnose prostate cancer. […] New biomarkers let us precisely find prostate cancer, guide treatment decisions, monitor response to treatment, and track the cancer’s growth. […] These are some of the new diagnostic tests available: […] The 4Kscore Test is a follow-up blood test given after an abnormal PSA test or DRE. It scores your risk for having aggressive prostate cancer. […] The Prostate Health Index (PHI) is a new combination of 3 blood tests. The PHI score gives information about the chances of finding cancer with a biopsy after an elevated PSA level. […] A urine test can find PCA3, a gene that is specific to prostate cancer.

• #26 Biomarkers for Prostate Cancer: From Diagnosis to Treatment

  https://www.mdpi.com/2075-4418/13/21/3350

  The PHI has shown exceptional proficiency in the examination of PCa, including more aggressive subtypes, surpassing both the total PSA and the percentage of free PSA. […] The 4K score is more accurate for diagnosing PCa in general and high-grade PCa specifically, compared to PSA or the percentage of free PSA. […] PCA3, also known as DD3, is a prostate-specific mRNA biomarker that has promising potential for the detection of prostate cancer (PCa). […] Urinary miRNAs have emerged as promising biomarkers for detecting prostate cancer (PCa), offering valuable tools to distinguish between malignant and benign tumors.

• #27 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a digital rectal exam, a healthcare professional inserts a gloved, lubricated finger into the rectum. The health professional feels the prostate gland for anything concerning in the texture, shape or size of the gland. […] A prostate-specific antigen test is a blood test that measures the amount of prostate-specific antigen in the blood. Prostate-specific antigen, also called PSA, is a substance that prostate cells make. Some PSA circulates in the blood. A PSA test detects the PSA in a blood sample. […] Having a high level of PSA in your blood can be a sign of prostate cancer. But many other things also can cause a high PSA level, including prostate infection and prostate enlargement. If a PSA test detects an increased level of PSA in your blood, the test is usually repeated. Your healthcare professional might recommend doing the test again in a few weeks to see if the level goes down. If the level stays high, you might need an imaging test or a biopsy procedure to look for signs of cancer.

• #28 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Diagnostic tools for prostate cancer have undergone significant advancements in recent years to improve the accuracy of prostate cancer detection and avoid overdiagnosis and subsequent overtreatment. Despite this, a suspicion of prostate cancer continues to arise from a raised serum prostate specific antigen (PSA) level, and/or a digital rectal examination (DRE). However, an elevated PSA alone should no longer necessitate a prostate biopsy. The use of diagnostic adjuncts can help to predict the presence of clinically significant prostate cancer thereby avoiding unnecessary biopsies in a proportion of patients. […] DRE can be used as an inexpensive diagnostic tool to check the prostate for cancer and to give an assessment of the prostate volume. It has the ability to detect prostate cancer with a volume of 0.2ml, if situated in the posterior peripheral zone, and can be used to raise suspicion irrespective of PSA. However, there is a high degree of interobserver variability, and a normal DRE does not eliminate the risk of a significant prostate cancer. An historical prospective multicenter trial found 18% of prostate cancers were detected solely by DRE, nowadays this figure is thought to be less. Nevertheless, an abnormal DRE is an indication for a prostate biopsy irrespective of the PSA.

• #29 Prostate Cancer Screening Tests | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html

  Most men without prostate cancer have PSA levels under 4 ng/mL of blood. When prostate cancer develops, the PSA level often goes above 4. Still, a level below 4 is not a guarantee that a man doesnt have cancer. About 15% of men with a PSA below 4 will have prostate cancer if a biopsy is done. […] Men with a PSA level between 4 and 10 (often called the borderline range) have about a 1 in 4 chance of having prostate cancer. […] If the PSA is more than 10, the chance of having prostate cancer is over 50%. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] DRE is less effective than the PSA blood test in finding prostate cancer, but it can sometimes find cancers in men with normal PSA levels. For this reason, it might be included as a part of prostate cancer screening.

• #30 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Diagnostic tools for prostate cancer have undergone significant advancements in recent years to improve the accuracy of prostate cancer detection and avoid overdiagnosis and subsequent overtreatment. Despite this, a suspicion of prostate cancer continues to arise from a raised serum prostate specific antigen (PSA) level, and/or a digital rectal examination (DRE). However, an elevated PSA alone should no longer necessitate a prostate biopsy. The use of diagnostic adjuncts can help to predict the presence of clinically significant prostate cancer thereby avoiding unnecessary biopsies in a proportion of patients. […] DRE can be used as an inexpensive diagnostic tool to check the prostate for cancer and to give an assessment of the prostate volume. It has the ability to detect prostate cancer with a volume of 0.2ml, if situated in the posterior peripheral zone, and can be used to raise suspicion irrespective of PSA. However, there is a high degree of interobserver variability, and a normal DRE does not eliminate the risk of a significant prostate cancer. An historical prospective multicenter trial found 18% of prostate cancers were detected solely by DRE, nowadays this figure is thought to be less. Nevertheless, an abnormal DRE is an indication for a prostate biopsy irrespective of the PSA.

• #31 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Diagnostic tools for prostate cancer have undergone significant advancements in recent years to improve the accuracy of prostate cancer detection and avoid overdiagnosis and subsequent overtreatment. Despite this, a suspicion of prostate cancer continues to arise from a raised serum prostate specific antigen (PSA) level, and/or a digital rectal examination (DRE). However, an elevated PSA alone should no longer necessitate a prostate biopsy. The use of diagnostic adjuncts can help to predict the presence of clinically significant prostate cancer thereby avoiding unnecessary biopsies in a proportion of patients. […] DRE can be used as an inexpensive diagnostic tool to check the prostate for cancer and to give an assessment of the prostate volume. It has the ability to detect prostate cancer with a volume of 0.2ml, if situated in the posterior peripheral zone, and can be used to raise suspicion irrespective of PSA. However, there is a high degree of interobserver variability, and a normal DRE does not eliminate the risk of a significant prostate cancer. An historical prospective multicenter trial found 18% of prostate cancers were detected solely by DRE, nowadays this figure is thought to be less. Nevertheless, an abnormal DRE is an indication for a prostate biopsy irrespective of the PSA.

• #32 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  Diagnostic tools for prostate cancer have undergone significant advancements in recent years to improve the accuracy of prostate cancer detection and avoid overdiagnosis and subsequent overtreatment. Despite this, a suspicion of prostate cancer continues to arise from a raised serum prostate specific antigen (PSA) level, and/or a digital rectal examination (DRE). However, an elevated PSA alone should no longer necessitate a prostate biopsy. The use of diagnostic adjuncts can help to predict the presence of clinically significant prostate cancer thereby avoiding unnecessary biopsies in a proportion of patients. […] DRE can be used as an inexpensive diagnostic tool to check the prostate for cancer and to give an assessment of the prostate volume. It has the ability to detect prostate cancer with a volume of 0.2ml, if situated in the posterior peripheral zone, and can be used to raise suspicion irrespective of PSA. However, there is a high degree of interobserver variability, and a normal DRE does not eliminate the risk of a significant prostate cancer. An historical prospective multicenter trial found 18% of prostate cancers were detected solely by DRE, nowadays this figure is thought to be less. Nevertheless, an abnormal DRE is an indication for a prostate biopsy irrespective of the PSA.

• #33 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a transrectal biopsy, a biopsy gun quickly projects a thin needle into suspect areas of the prostate gland, and small sections of tissue are removed for analysis. […] A biopsy is a procedure to remove a sample of tissue for testing in a lab. A prostate biopsy involves removing tissue from the prostate. It’s the only way to know for sure whether there is cancer in the prostate. […] Prostate tissue samples go to a lab for testing. In the lab, tests can show whether samples contain cancer. […] The Gleason score and grade group are numbers that tell your healthcare team whether your prostate cancer is growing slowly or quickly. How quickly a cancer grows also is called a cancer’s grade. […] To decide on the grade, doctors in the lab, called pathologists, look at the prostate cancer cells from a prostate biopsy.

• #34

  https://www.nhs.uk/conditions/prostate-cancer/diagnosis/

  If you have a raised PSA level, your doctor may refer you to hospital for an MRI scan of your prostate. If the scan shows a problem, it can be targeted later with a biopsy. […] A biopsy may also be taken during a cystoscopy examination. […] Although a biopsy is more reliable than a PSA test, there can still be issues, such as: missing the cancer doctors can see the prostate using the ultrasound scan but might not always spot a tumour, needing another biopsy if your symptoms persist or your PSA level continues to rise you may be offered another MRI scan first, finding small, low-risk cancers that do not need treatment but may cause you anxiety and there is a possible related risk that you choose to undergo surgery or radiotherapy of little to no benefit that cause side effects, such as incontinence and erectile dysfunction (impotence).

• #35 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #36 Prostate cancer diagnosis – the new pathway – Prostate Matters

  https://prostatematters.co.uk/diagnosis-of-prostate-cancer/molecular-diagnostic-test-for-prostate-cancer/prostate-cancer-diagnosis-the-pathway/

  The gold standard or the best way to diagnose prostate cancer is a 3T multiparametric MRI (mpMRI) and an MRI-targeted transperineal biopsy in those that need it, with additional samples taken from areas that look normal on MRI. […] The MRI scan should be multi-parametric ie it should use a number of parameters, including anatomical imaging (T1 and T2 weighted); diffusion weighted imaging (which assesses the movement of water, which we know is restricted in areas of cancer) and contrast enhanced imaging (many prostate cancers take up contrast quickly and release it quickly, because of their good blood supply). […] The MRI will be assigned a score. Any areas scoring 4 or 5 should be biopsied, as a cancer is likely (but not definite) in these areas. […] When a decision to do a biopsy has been made, then the way that the biopsy is done should be considered.

• #37 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #38 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #39 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #40 Tests for prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/tests-for-prostate-cancer

  Depending on the results of your tests, your GP might refer you to a specialist. You usually see a urologist. This is a doctor who specialises in treating problems of the urinary tract system such as the prostate, bladder and kidneys. […] The first scan your specialist does is an MRI scan. This is usually a multiparametric MRI scan (mpMRI). […] It is important to know that an MRI alone cant tell for sure whether you have prostate cancer or not. But the results help your doctor decide whether you need further tests. […] A doctor who specialises in imaging scans gives the MRI scan a score based on the results. This score helps your doctor decide on the next step and whether you need to have a biopsy. […] Your doctor may not recommend a biopsy if you have a low Likert score. […] This result on its own doesnt mean that you definitely have prostate cancer. But its more likely that you do. Your doctor is likely to recommend for you to have a biopsy.

• #41 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #42 Tests for prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/tests-for-prostate-cancer

  Depending on the results of your tests, your GP might refer you to a specialist. You usually see a urologist. This is a doctor who specialises in treating problems of the urinary tract system such as the prostate, bladder and kidneys. […] The first scan your specialist does is an MRI scan. This is usually a multiparametric MRI scan (mpMRI). […] It is important to know that an MRI alone cant tell for sure whether you have prostate cancer or not. But the results help your doctor decide whether you need further tests. […] A doctor who specialises in imaging scans gives the MRI scan a score based on the results. This score helps your doctor decide on the next step and whether you need to have a biopsy. […] Your doctor may not recommend a biopsy if you have a low Likert score. […] This result on its own doesnt mean that you definitely have prostate cancer. But its more likely that you do. Your doctor is likely to recommend for you to have a biopsy.

• #43 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #44 New technology promises precise diagnosis, less invasive treatment for prostate cancer – Medical Update

  https://medicalupdate.pennstatehealth.org/urology-surgery/prostate-cancer-treatment/

  Penn State Health is one of the few programs in the region to offer multiparametric MRI-transrectal ultrasound image-guided fusion prostate biopsy, or MRI fusion biopsy, which is a more efficient and accurate means of prostate cancer diagnosis when compared with conventional biopsy. […] Dr. Aminsharifi explained that performing preliminary mpMRI before biopsy allows physicians to omit biopsy for select patients altogether. […] If MRI is negative with a sensitivity of 90%, the patient likely does not have significant prostate cancer. […] If biopsy is needed, mpMRI offers precise delineation and staging of suspected cancer. […] The fusion of mpMRI with transrectal ultrasound image guidance also helps with surgical planning. […] Using this approach for patients who already have a diagnosis of prostate cancer, the urologist can more accurately stage the cancer, assess its size, and determine its relationship to nearby structures, such as neurovascular bundles and the seminal vesicle.

• #45 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #46 Prostate cancer diagnosis – the new pathway – Prostate Matters

  https://prostatematters.co.uk/diagnosis-of-prostate-cancer/molecular-diagnostic-test-for-prostate-cancer/prostate-cancer-diagnosis-the-pathway/

  Non-invasive mpMRI scans and reports provide a picture of potential cancer lesions. […] Whilst 3T MRI provides the best quality image, only a few centres have these machines. […] The PROMIS study compared MRI with both the standard transrectal biopsy and a 5mm template mapping biopsy. […] The PRECISION study randomised men to either a standard biopsy or an MRI, and a targeted biopsy in men who had a suspicious area on MRI. […] This showed that an MRI-targeted biopsy found more of the clinically significant cancers and fewer insignificant cancers than the standard approach, and that around 1 in 4 men could avoid a biopsy if they had an MRI that was low risk. […] The current NICE Guidelines from 2014 have been superseded.

• #47 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  Doctors recommend that some men with prostate cancer consider genetic counseling and testing to look for certain inherited gene changes. […] Imaging tests use x-rays, magnetic fields, sound waves, or radioactive substances to create pictures of the inside of your body. […] A lymph node biopsy is rarely done as a separate procedure. It’s sometimes used when a radical prostatectomy isn’t planned, but when it’s still important to know if the lymph nodes contain cancer.

• #48 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  Your healthcare team uses your grade group to decide on your cancer’s stage. The grade group also can help your care team plan your treatment. […] Biomarkers are things that can be detected in the body. Results from biomarker tests tell healthcare professionals about what’s going on inside the body. Biomarker testing for cancer looks for biomarkers in the cancer cells. The results help healthcare professionals learn more about what’s going on inside the cancer cells. […] Imaging tests can look for signs that the cancer has spread beyond the prostate. These tests might detect cancer that has spread to the lymph nodes or to other parts of the body. […] Your healthcare team uses the results of your tests and procedures to give your cancer a stage. The cancer’s stage tells your healthcare team about the size of the cancer and how quickly it’s growing.

• #49 Tests for prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/tests-for-prostate-cancer

  During a biopsy, your doctor takes samples of tissue from your prostate. They send the samples to a laboratory and a doctor looks at them under a microscope to check for cancer. […] A positive biopsy means that they have found cancer cells. […] If you have a biopsy that shows that you have cancer cells in your prostate, then you may have more tests to work out where and how big the cancer is. This is called staging the cancer. […] You might have a CT scan to find out whether the cancer is in the prostate only or whether it has spread to other parts of your body. […] A bone scan shows up changes or abnormalities in the bones. You might have a bone scan to find out if prostate cancer has spread to the bones. […] The tests you have helps your doctor find out if you have prostate cancer and how far it has grown. This is the stage of the cancer. This is important because doctors recommend your treatment according to the stage of the cancer.

• #50 Diagnosis and Stages of Prostate Cancer – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/cancer/prostate-cancer/diagnosis-and-stages

  After receiving a diagnosis of prostate cancer, our team will try to determine your stage of cancer. The stage of cancer describes how much and far the cancer has spread in your body. It is one of the most important things to know when deciding how to best treat your cancer, including whether your cancer can be removed (resected) with surgery. You may need additional diagnostic tests to help our team formally assign a stage to your cancer, which is dependent upon the size and spread of the cancer. […] The Gleason Grading System is commonly used to determine the aggressiveness of prostate cancer, ranging from least to most aggressive with a score from 210. A higher number, such as 10, means a more advanced cancer. […] After your healthcare team identifies your stage of prostate cancer, they may also want to use any of the following post-diagnostic tests to learn more about your cancer: Computed tomography (CT or CAT) scan, a test which uses a combination of X-rays and software to create images of your prostate and nearby organs. It will help to discover if your cancer has spread into lymph nodes or other organs, Prostate-specific membrane antigen (PSMA) PET scan is an imaging test where radioactive tracers attach to PSMA, a protein found on most prostate cancer cells. This scan is especially helpful to determine if or where your prostate cancer has spread, Magnetic resonance imaging (MRI), a test which uses magnets and radio waves to create detailed images of your prostate and nearby organs and tissues. […] Lymph node biopsy, a test that examines if your prostate cancer has spread to nearby lymph nodes; small pieces of tissue are tested under a microscope.

• #51 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  Most prostate cancers are first found as a result of screening. Early prostate cancers usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. […] If prostate cancer is suspected based on results of screening tests or symptoms, tests will be needed to be sure. […] The actual diagnosis of prostate cancer can only be made with a prostate biopsy. […] The PSA blood test can be used to screen for prostate cancer in men without symptoms. It’s also one of the first tests done in men who have symptoms that might be caused by prostate cancer. […] If your PSA level is high, you might need further tests to look for prostate cancer. […] If the results of a PSA blood test, DRE, or other tests suggest that you might have prostate cancer, you will most likely need a prostate biopsy.

• #52 Diagnosing Prostate Cancer | Prostate Cancer | CDC

  https://www.cdc.gov/prostate-cancer/diagnosis/index.html

  A biopsy is the main tool for diagnosing prostate cancer. […] A biopsy is a procedure that can be used to diagnose prostate cancer. A biopsy is when a small piece of tissue is removed from the prostate and looked at under a microscope to see if there are cancer cells. […] A biopsy is the main tool for diagnosing prostate cancer, but a doctor can use other tools to help make sure the biopsy is made in the right place. […] If prostate cancer is diagnosed, other tests are done to find out if cancer cells have spread within the prostate or to other parts of the body. This process is called staging. […] The stage of prostate cancer tells doctors what kind of treatment you need.

• #53 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #54 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Different risk calculators and nomograms that aggregate data were developed in an attempt to better estimate tumor stage and aggressiveness. […] The gold standard to diagnose PCa with an elevated PSA is the 12 core extended sextant TRUS, the TRUS-guided prostate needle biopsy. […] A recent meta-analysis demonstrated that MRI-targeted biopsy significantly increases the detection rate of clinically significant cancers and decreases the detection on indolent cancers. […] After a complete clinical workup, clinicians should classify patients according to different major classifications (D’Amico, EAU, NCCN).

• #55 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #56 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a transrectal biopsy, a biopsy gun quickly projects a thin needle into suspect areas of the prostate gland, and small sections of tissue are removed for analysis. […] A biopsy is a procedure to remove a sample of tissue for testing in a lab. A prostate biopsy involves removing tissue from the prostate. It’s the only way to know for sure whether there is cancer in the prostate. […] Prostate tissue samples go to a lab for testing. In the lab, tests can show whether samples contain cancer. […] The Gleason score and grade group are numbers that tell your healthcare team whether your prostate cancer is growing slowly or quickly. How quickly a cancer grows also is called a cancer’s grade. […] To decide on the grade, doctors in the lab, called pathologists, look at the prostate cancer cells from a prostate biopsy.

• #57 Current Diagnostics for Prostate Cancer – Prostate Cancer – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK571327/

  The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) imaging. Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer. A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65-94%. Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score. One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers. This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of 3 could have avoided a biopsy in 27% of patients.

• #58 Prostate cancer diagnosis – the new pathway – Prostate Matters

  https://prostatematters.co.uk/diagnosis-of-prostate-cancer/molecular-diagnostic-test-for-prostate-cancer/prostate-cancer-diagnosis-the-pathway/

  If an MRI has been done then a transrectal approach can be used to target the lesion seen on MRI, and to take systematic samples as well. […] None of the ways has been shown to be better than another, so that those who use software to target an MRI lesion have similar rates of cancer detection as those who are expert at biopsying using visual registration. […] Biopsies can be taken either via the rectum (transrectal biopsy) or through the perineum, which is the skin between the back passage and the scrotum (transperineal). […] The transperineal method has a lower risk of infection (0.2% compared to 2-4%) than a transrectal approach. […] When systematic biopsies are done transrectally it is common to take 5 or 6 cores from each of the right and left side of the prostate. […] For those hospitals that have a transperineal only approach, this can be done either under local anaesthetic (an injection in the skin and tissue around the prostate) or with additional sedation, similar to a light general anesthetic.

• #59 Prostate cancer diagnosis – the new pathway – Prostate Matters

  https://prostatematters.co.uk/diagnosis-of-prostate-cancer/molecular-diagnostic-test-for-prostate-cancer/prostate-cancer-diagnosis-the-pathway/

  If an MRI has been done then a transrectal approach can be used to target the lesion seen on MRI, and to take systematic samples as well. […] None of the ways has been shown to be better than another, so that those who use software to target an MRI lesion have similar rates of cancer detection as those who are expert at biopsying using visual registration. […] Biopsies can be taken either via the rectum (transrectal biopsy) or through the perineum, which is the skin between the back passage and the scrotum (transperineal). […] The transperineal method has a lower risk of infection (0.2% compared to 2-4%) than a transrectal approach. […] When systematic biopsies are done transrectally it is common to take 5 or 6 cores from each of the right and left side of the prostate. […] For those hospitals that have a transperineal only approach, this can be done either under local anaesthetic (an injection in the skin and tissue around the prostate) or with additional sedation, similar to a light general anesthetic.

• #60 New technology promises precise diagnosis, less invasive treatment for prostate cancer – Medical Update

  https://medicalupdate.pennstatehealth.org/urology-surgery/prostate-cancer-treatment/

  Penn State Health is one of the few programs in the region to offer multiparametric MRI-transrectal ultrasound image-guided fusion prostate biopsy, or MRI fusion biopsy, which is a more efficient and accurate means of prostate cancer diagnosis when compared with conventional biopsy. […] Dr. Aminsharifi explained that performing preliminary mpMRI before biopsy allows physicians to omit biopsy for select patients altogether. […] If MRI is negative with a sensitivity of 90%, the patient likely does not have significant prostate cancer. […] If biopsy is needed, mpMRI offers precise delineation and staging of suspected cancer. […] The fusion of mpMRI with transrectal ultrasound image guidance also helps with surgical planning. […] Using this approach for patients who already have a diagnosis of prostate cancer, the urologist can more accurately stage the cancer, assess its size, and determine its relationship to nearby structures, such as neurovascular bundles and the seminal vesicle.

• #61 Prostate Cancer Diagnosis | NYU Langone Health

  https://nyulangone.org/conditions/prostate-cancer/diagnosis

  A biopsy—a series of tissue samples collected from the prostate—can allow your doctor to confirm a diagnosis of prostate cancer. […] Transrectal ultrasound-guided biopsy is a valuable tool in diagnosing prostate cancer, but because alone it may miss aggressive cancers in areas of the prostate that are not sampled, NYU Langone doctors typically pair it with MRI imaging. […] Our doctors are among the country’s most experienced in using a state-of-the-art technology called MRI-ultrasound fusion targeted biopsy, which combines MRI with ultrasound to create a three-dimensional biopsy image of the prostate. […] A computerized template biopsy uses ultrasound imaging to create a three-dimensional map of the prostate. The template allows urologists to obtain more precise tissue samples, making it more accurate than a traditional biopsy. […] If doctors suspect cancer has spread, they may order a prostate-specific membrane antigen PET/MRI or PET/CT scan—a CT scan uses a series of X-ray images and computer software to create three-dimensional, cross-sectional images.

• #62 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Different risk calculators and nomograms that aggregate data were developed in an attempt to better estimate tumor stage and aggressiveness. […] The gold standard to diagnose PCa with an elevated PSA is the 12 core extended sextant TRUS, the TRUS-guided prostate needle biopsy. […] A recent meta-analysis demonstrated that MRI-targeted biopsy significantly increases the detection rate of clinically significant cancers and decreases the detection on indolent cancers. […] After a complete clinical workup, clinicians should classify patients according to different major classifications (D’Amico, EAU, NCCN).

• #63 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  Diagnosis of prostate cancer is a four-step process. If the PSA levels in your blood test suggest the possibility that you may have prostate cancer, your physician will order a biopsy. If there is cancer present in the biopsy samples, it will be given a Gleason score and stage-two numbers that indicate the extent and aggressiveness of the cancer. […] Your prostate cancer screening includes a test to measure the levels of prostate-specific antigen (PSA) in your blood. Elevated PSA levels are often an early indication of prostate cancer as well as other prostate disorders. […] While the PSA test helps assess the risk of prostate cancer, the prostate biopsy is the only way to make an accurate diagnosis. If either your digital rectal exam or blood test had an abnormal result, your physician will often order a biopsy.

• #64 Prostate Cancer Screening (PDQ®) – NCI

  https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq

  The data on MRI-guided biopsy have been reported primarily by experienced MRI radiologists and urologists in referral centers, and generalizability of results is uncertain. A multicenter trial randomly assigned 500 men with clinical suspicion of prostate cancer to either a systematic biopsy or MRI-guided biopsy. For the latter, men received MRI and then subsequent MRI-guided biopsy if the MRI was suggestive of prostate cancer. There were more men with a Gleason score of 7 or less (95 vs. 64) and fewer men with a Gleason score of less than 7 (23 vs. 55) in the MRI group compared with the systematic biopsy group, with fewer biopsies overall in the MRI group. […] A large, single-arm, single-center study of 2,103 men with MRI-visible lesions who underwent both MRI-directed biopsies and standard systematic prostate needle biopsies under ultrasound visualization showed that MRI-directed biopsy alone detected more clinically significant (Gleason score of 4+3 or higher) disease than did systematic biopsy alone. Of 466 men with clinically significant disease that was detected on either type of biopsy modality, MRI-guided biopsy correctly classified 91% of them as clinically significant, while systematic biopsy correctly classified 62% of them as clinically significant. Of all the men studied, 1.9% of men would have had clinically significant disease missed (or misclassified as clinically insignificant disease) if they underwent MRI-guided biopsy alone, compared with 8.3% of men if they underwent systematic biopsy alone.

• #65 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #66 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a transrectal biopsy, a biopsy gun quickly projects a thin needle into suspect areas of the prostate gland, and small sections of tissue are removed for analysis. […] A biopsy is a procedure to remove a sample of tissue for testing in a lab. A prostate biopsy involves removing tissue from the prostate. It’s the only way to know for sure whether there is cancer in the prostate. […] Prostate tissue samples go to a lab for testing. In the lab, tests can show whether samples contain cancer. […] The Gleason score and grade group are numbers that tell your healthcare team whether your prostate cancer is growing slowly or quickly. How quickly a cancer grows also is called a cancer’s grade. […] To decide on the grade, doctors in the lab, called pathologists, look at the prostate cancer cells from a prostate biopsy.

• #67 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #68 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a transrectal biopsy, a biopsy gun quickly projects a thin needle into suspect areas of the prostate gland, and small sections of tissue are removed for analysis. […] A biopsy is a procedure to remove a sample of tissue for testing in a lab. A prostate biopsy involves removing tissue from the prostate. It’s the only way to know for sure whether there is cancer in the prostate. […] Prostate tissue samples go to a lab for testing. In the lab, tests can show whether samples contain cancer. […] The Gleason score and grade group are numbers that tell your healthcare team whether your prostate cancer is growing slowly or quickly. How quickly a cancer grows also is called a cancer’s grade. […] To decide on the grade, doctors in the lab, called pathologists, look at the prostate cancer cells from a prostate biopsy.

• #69 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #70 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  During a transrectal biopsy, a biopsy gun quickly projects a thin needle into suspect areas of the prostate gland, and small sections of tissue are removed for analysis. […] A biopsy is a procedure to remove a sample of tissue for testing in a lab. A prostate biopsy involves removing tissue from the prostate. It’s the only way to know for sure whether there is cancer in the prostate. […] Prostate tissue samples go to a lab for testing. In the lab, tests can show whether samples contain cancer. […] The Gleason score and grade group are numbers that tell your healthcare team whether your prostate cancer is growing slowly or quickly. How quickly a cancer grows also is called a cancer’s grade. […] To decide on the grade, doctors in the lab, called pathologists, look at the prostate cancer cells from a prostate biopsy.

• #71 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  A biopsy is a procedure in which small samples of the prostate are removed and looked at with a microscope. […] Your biopsy samples will be sent to a lab, where a doctor with special training, called a pathologist, will look at them with a microscope to see if they contain cancer cells. […] If the prostate biopsy results are negative (that is, if they don’t show cancer), and the chance that you have prostate cancer isn’t very high based on your PSA level and other tests, you might not need any more tests, other than repeat PSA tests. […] If prostate cancer is found on a biopsy, it will be assigned a grade. […] The Gleason system, which has been in use for many years, assigns grades using the numbers 1 through 5, based on how much the cancer looks like normal prostate tissue. […] The outcomes for men with prostate cancer can be divided into more than just the 3 groups mentioned above.

• #72 Prostate Cancer Diagnosis – Virginia Oncology

  https://www.virginiacancer.com/prostate-cancer/testing-diagnosis/

  Transrectal biopsy: A biopsy is the removal of tissue to look for cancer cells. Its the only sure way to diagnose prostate cancer. The doctor inserts needles through the rectum into the prostate. The doctor removes small tissue samples (called cores) from many areas of the prostate. […] If cancer cells are found, the pathologist studies tissue samples from the prostate under a microscope to report the grade of the tumor. The grade tells how much the tumor tissue differs from normal prostate tissue. It suggests how fast the tumor is likely to grow. Tumors with higher grades tend to grow faster than those with lower grades. They are also more likely to spread. […] One system of grading is the Gleason score. Gleason scores range from 2 to 10. […] A high Gleason score (such as 10) means a high-grade prostate tumor. High-grade tumors are more likely than low-grade tumors to grow quickly and spread.

• #73 Prostate Cancer – Symptoms, Diagnosis, & Treatment Options

  https://www.advancedurologyinstitute.com/condition/prostate-cancer/

  One in eight men in the U.S. will be diagnosed with prostate cancer during his lifetime. The earlier it is detected, the more options for treatment and the higher the chance of survival. […] During your visit, your doctor will ask you questions regarding your medical, surgical, and family history, and perform an exam. […] Lab tests will often be performed including PSA, and urine studies. […] If cancer cells are found, a pathologist studies the tissue samples under a microscope to determine the grade of the tumor. This tells how much the tumor tissue differs from normal prostate tissue. It suggests how fast the tumor is likely to grow. Imaging is often needed after the diagnosis of prostate cancer: CT, MRI, and/or bone scan. […] The most commonly used system for grading the aggressiveness of prostate cancer is the Gleason score. Gleason scores range from 2 to 10. A high Gleason score indicates a high-grade prostate tumor, which is more likely to grow quickly and spread.

• #74 Prostate cancer

  https://www.cancervic.org.au/cancer-information/types-of-cancer/prostate_cancer/diagnosing_prostate_cancer.html

  The biopsy results will show the grade of the cancer. […] For many years, the Gleason scoring system has been used to grade the tissue taken during a biopsy. […] Based on the size and grade of the cancer, and your PSA level before the biopsy, localised (early) prostate cancer will be classified as low risk, intermediate risk, or high risk. […] Prostate cancer often grows slowly, and even the more aggressive cases of prostate cancer tend to grow more slowly than other types of cancer. […] Compared with other cancers, prostate cancer has one of the highest five-year survival rates if diagnosed early.

• #75 Prostate Cancer Tests for Diagnosis & Screening

  https://www.cancercenter.com/cancer-types/prostate-cancer/diagnosis-and-detection

  Prostate cancer is often detected during the course of a routine prostate exam and/or the PSA blood test, but diagnosing it may require other procedures. […] PSA is a protein found in prostate cells that helps to keep semen liquified. Most cases of prostate cancer develop in these cells, so an elevated PSA count may be a sign of prostate cancer. However, PSA results are more of an indicator than a firm diagnostic tooltheres not a certain PSA score that means a man has prostate cancer. […] Depending on the results of the PSA and DRE, the doctor may order a prostate biopsy. […] If a biopsy sample is found to contain cancer, the pathologist analyzing the specimen takes a deeper look at the cancer cells to determine how aggressive the disease is likely to be. […] Prostate cancers are assigned a Gleason score depending on how abnormal the cells look.

• #76 Prostate Cancer – Symptoms, Diagnosis, & Treatment Options

  https://www.advancedurologyinstitute.com/condition/prostate-cancer/

  One in eight men in the U.S. will be diagnosed with prostate cancer during his lifetime. The earlier it is detected, the more options for treatment and the higher the chance of survival. […] During your visit, your doctor will ask you questions regarding your medical, surgical, and family history, and perform an exam. […] Lab tests will often be performed including PSA, and urine studies. […] If cancer cells are found, a pathologist studies the tissue samples under a microscope to determine the grade of the tumor. This tells how much the tumor tissue differs from normal prostate tissue. It suggests how fast the tumor is likely to grow. Imaging is often needed after the diagnosis of prostate cancer: CT, MRI, and/or bone scan. […] The most commonly used system for grading the aggressiveness of prostate cancer is the Gleason score. Gleason scores range from 2 to 10. A high Gleason score indicates a high-grade prostate tumor, which is more likely to grow quickly and spread.

• #77 Prostate Cancer Diagnosis – Virginia Oncology

  https://www.virginiacancer.com/prostate-cancer/testing-diagnosis/

  Transrectal biopsy: A biopsy is the removal of tissue to look for cancer cells. Its the only sure way to diagnose prostate cancer. The doctor inserts needles through the rectum into the prostate. The doctor removes small tissue samples (called cores) from many areas of the prostate. […] If cancer cells are found, the pathologist studies tissue samples from the prostate under a microscope to report the grade of the tumor. The grade tells how much the tumor tissue differs from normal prostate tissue. It suggests how fast the tumor is likely to grow. Tumors with higher grades tend to grow faster than those with lower grades. They are also more likely to spread. […] One system of grading is the Gleason score. Gleason scores range from 2 to 10. […] A high Gleason score (such as 10) means a high-grade prostate tumor. High-grade tumors are more likely than low-grade tumors to grow quickly and spread.

• #78 Detecting & Diagnosing Prostate Cancer | WVCI

  https://www.oregoncancer.com/prostate-cancer/diagnosis

  Your doctor can check for prostate cancer before you have any symptoms. […] The digital rectal exam and PSA test can detect a problem in the prostate. However, they cant show whether the problem is cancer or a less serious condition. […] Transrectal biopsy: A biopsy is the removal of tissue to look for cancer cells. Its the only sure way to diagnose prostate cancer. […] If cancer cells are found, the pathologist studies tissue samples from the prostate under a microscope to report the grade of the tumor. […] Doctors use tumor grade along with your age and other factors to suggest treatment options. […] A high Gleason score (such as 10) means a high-grade prostate tumor. High-grade tumors are more likely than low-grade tumors to grow quickly and spread.

• #79 Diagnosis of prostate cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/prostate/diagnosis

  A prostate biopsy may be done if the doctor finds an abnormal area during a DRE or TRUS. It may also be done if the PSA level is higher than normal or has gone up over time. […] The samples collected during a prostate biopsy are sent to the lab. The pathology report will say if cancer cells are in the sample. A positive biopsy means that cancer cells were found. A negative biopsy means that no cancer cells were found. If you have a negative biopsy, your doctor may do a repeat biopsy because in some cases a biopsy can miss cancer. […] An MRI is used to look for cancer in the front of the prostate that may be missed with other tests. […] A bone scan is used to look for prostate cancer that has spread to the bones. […] A CT scan can be used to look for cancer that has spread outside of the prostate, such as to the chest, abdomen or pelvis.

• #80 Tests for prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/tests-for-prostate-cancer

  During a biopsy, your doctor takes samples of tissue from your prostate. They send the samples to a laboratory and a doctor looks at them under a microscope to check for cancer. […] A positive biopsy means that they have found cancer cells. […] If you have a biopsy that shows that you have cancer cells in your prostate, then you may have more tests to work out where and how big the cancer is. This is called staging the cancer. […] You might have a CT scan to find out whether the cancer is in the prostate only or whether it has spread to other parts of your body. […] A bone scan shows up changes or abnormalities in the bones. You might have a bone scan to find out if prostate cancer has spread to the bones. […] The tests you have helps your doctor find out if you have prostate cancer and how far it has grown. This is the stage of the cancer. This is important because doctors recommend your treatment according to the stage of the cancer.

• #81 Prostate cancer

  https://www.cancervic.org.au/cancer-information/types-of-cancer/prostate_cancer/diagnosing_prostate_cancer.html

  Depending on the results of the MRI scan, your urologist may recommend you have a biopsy to remove some samples of tissue from the prostate. […] The biopsy samples are sent to a laboratory, where a specialist doctor called a pathologist looks for cancer cells in the tissue. […] If the MRI or other biopsy results show prostate cancer, other tests may be done to work out whether the cancer has spread. […] A PET (positron emission tomography) scan combined with a CT scan is a specialised imaging test. […] This scan can show if prostate cancer has spread to your bones. […] A CT (computerised tomography) scan uses x-rays to create detailed pictures of the inside of the body. […] Tests help your doctors work out if you have prostate cancer and whether it has spread. […] The most common staging system for prostate cancer is the TNM system.

• #82 Diagnosis and Stages of Prostate Cancer – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/cancer/prostate-cancer/diagnosis-and-stages

  After receiving a diagnosis of prostate cancer, our team will try to determine your stage of cancer. The stage of cancer describes how much and far the cancer has spread in your body. It is one of the most important things to know when deciding how to best treat your cancer, including whether your cancer can be removed (resected) with surgery. You may need additional diagnostic tests to help our team formally assign a stage to your cancer, which is dependent upon the size and spread of the cancer. […] The Gleason Grading System is commonly used to determine the aggressiveness of prostate cancer, ranging from least to most aggressive with a score from 210. A higher number, such as 10, means a more advanced cancer. […] After your healthcare team identifies your stage of prostate cancer, they may also want to use any of the following post-diagnostic tests to learn more about your cancer: Computed tomography (CT or CAT) scan, a test which uses a combination of X-rays and software to create images of your prostate and nearby organs. It will help to discover if your cancer has spread into lymph nodes or other organs, Prostate-specific membrane antigen (PSMA) PET scan is an imaging test where radioactive tracers attach to PSMA, a protein found on most prostate cancer cells. This scan is especially helpful to determine if or where your prostate cancer has spread, Magnetic resonance imaging (MRI), a test which uses magnets and radio waves to create detailed images of your prostate and nearby organs and tissues. […] Lymph node biopsy, a test that examines if your prostate cancer has spread to nearby lymph nodes; small pieces of tissue are tested under a microscope.

• #83 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  Staging of prostate cancer is based on the following five key pieces of information: The extent of the primary tumor (T category), whether the cancer has spread to nearby lymph nodes (N category), the absence or presence of distant metastasis (M category), the PSA level at the time of diagnosis, and the Grade Group, based on prostate biopsy (or surgery). […] Since the adoption of widespread screening, prostate cancer is being diagnosed earlier in the disease course. […] The American Cancer Society (ACS) estimated that 240,890 new cases of prostate cancer were diagnosed in the United States in 2011 and that 33,720 men died of the disease in that year. […] Prostate-specific antigen (PSA) measurement is an essential component of a modern screening program. […] The indications for screening are controversial.

• #84 Prostate cancer – Wikipedia

  https://en.wikipedia.org/wiki/Prostate_cancer

  A definitive diagnosis of prostate cancer requires a biopsy of the prostate. Prostate biopsies are typically taken by a needle passing through the rectum or perineum, guided by transrectal ultrasonography, MRI, or a combination of the two. […] The extent of cancer spread is assessed by MRI or PSMA scan a positron emission tomography (PET) imaging technique where a radioactive label that binds the prostate protein prostate-specific membrane antigen is used to detect metastases distant from the prostate. […] After diagnosis, the tumor is staged to determine the extent of its growth and spread. Prostate cancer is typically staged using the American Joint Committee on Cancer’s (AJCC) three-component TNM system, with scores assigned for the extent of the tumor (T), spread to any lymph nodes (N), and the presence of metastases (M).

• #85 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  Prostate cancer stages range from 1 to 4. A lower number means the cancer is small and only in the prostate. A lower number stage typically means the cancer is very likely to be cured. If the cancer grows larger or spreads, the stage goes up. A higher number stage may mean a cure is less likely. […] The chance of surviving prostate cancer is quite good for most people. To understand prostate cancer survival rates, experts study many people with prostate cancer to see how many are living five years after their diagnosis. […] When the cancer is only in the prostate, the chance of surviving at least five years is 100%. As the cancer spreads beyond the prostate, the chances get lower. When prostate cancer has spread to other parts of the body, called metastatic prostate cancer, the chances of surviving at least five years is about 37%.

• #86 Diagnosis and Stages of Prostate Cancer – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/cancer/prostate-cancer/diagnosis-and-stages

  After receiving a diagnosis of prostate cancer, our team will try to determine your stage of cancer. The stage of cancer describes how much and far the cancer has spread in your body. It is one of the most important things to know when deciding how to best treat your cancer, including whether your cancer can be removed (resected) with surgery. You may need additional diagnostic tests to help our team formally assign a stage to your cancer, which is dependent upon the size and spread of the cancer. […] The Gleason Grading System is commonly used to determine the aggressiveness of prostate cancer, ranging from least to most aggressive with a score from 210. A higher number, such as 10, means a more advanced cancer. […] After your healthcare team identifies your stage of prostate cancer, they may also want to use any of the following post-diagnostic tests to learn more about your cancer: Computed tomography (CT or CAT) scan, a test which uses a combination of X-rays and software to create images of your prostate and nearby organs. It will help to discover if your cancer has spread into lymph nodes or other organs, Prostate-specific membrane antigen (PSMA) PET scan is an imaging test where radioactive tracers attach to PSMA, a protein found on most prostate cancer cells. This scan is especially helpful to determine if or where your prostate cancer has spread, Magnetic resonance imaging (MRI), a test which uses magnets and radio waves to create detailed images of your prostate and nearby organs and tissues. […] Lymph node biopsy, a test that examines if your prostate cancer has spread to nearby lymph nodes; small pieces of tissue are tested under a microscope.

• #87 Prostate Cancer Screening & Diagnosis – cCARE

  https://ccare.com/prostate-screening-diagnosis/

  Pathologists determine the Gleason score at the time of the prostate biopsy. […] Prostate cancer diagnosis can involve many variables, including PSA, DRE and biopsy results, tumor type and an individuals specific condition. […] Prostate cancer stages: Stage I, low-grade cancer cells in less than 5 percent of the prostate tissue; Stage II, more extensive cancer but still confined to the prostate; Stage III, the tumor has grown beyond the capsule of connective tissue that surrounds the prostate; Stage IV, prostate cancer has spread to other organs in the body.

• #88 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  Staging of prostate cancer is based on the following five key pieces of information: The extent of the primary tumor (T category), whether the cancer has spread to nearby lymph nodes (N category), the absence or presence of distant metastasis (M category), the PSA level at the time of diagnosis, and the Grade Group, based on prostate biopsy (or surgery). […] Since the adoption of widespread screening, prostate cancer is being diagnosed earlier in the disease course. […] The American Cancer Society (ACS) estimated that 240,890 new cases of prostate cancer were diagnosed in the United States in 2011 and that 33,720 men died of the disease in that year. […] Prostate-specific antigen (PSA) measurement is an essential component of a modern screening program. […] The indications for screening are controversial.

• #89 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  Doctors recommend that some men with prostate cancer consider genetic counseling and testing to look for certain inherited gene changes. […] Imaging tests use x-rays, magnetic fields, sound waves, or radioactive substances to create pictures of the inside of your body. […] A lymph node biopsy is rarely done as a separate procedure. It’s sometimes used when a radical prostatectomy isn’t planned, but when it’s still important to know if the lymph nodes contain cancer.

• #90 Diagnosis of prostate cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/prostate/diagnosis

  A prostate biopsy may be done if the doctor finds an abnormal area during a DRE or TRUS. It may also be done if the PSA level is higher than normal or has gone up over time. […] The samples collected during a prostate biopsy are sent to the lab. The pathology report will say if cancer cells are in the sample. A positive biopsy means that cancer cells were found. A negative biopsy means that no cancer cells were found. If you have a negative biopsy, your doctor may do a repeat biopsy because in some cases a biopsy can miss cancer. […] An MRI is used to look for cancer in the front of the prostate that may be missed with other tests. […] A bone scan is used to look for prostate cancer that has spread to the bones. […] A CT scan can be used to look for cancer that has spread outside of the prostate, such as to the chest, abdomen or pelvis.

• #91 Diagnosis of prostate cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/prostate/diagnosis

  A prostate biopsy may be done if the doctor finds an abnormal area during a DRE or TRUS. It may also be done if the PSA level is higher than normal or has gone up over time. […] The samples collected during a prostate biopsy are sent to the lab. The pathology report will say if cancer cells are in the sample. A positive biopsy means that cancer cells were found. A negative biopsy means that no cancer cells were found. If you have a negative biopsy, your doctor may do a repeat biopsy because in some cases a biopsy can miss cancer. […] An MRI is used to look for cancer in the front of the prostate that may be missed with other tests. […] A bone scan is used to look for prostate cancer that has spread to the bones. […] A CT scan can be used to look for cancer that has spread outside of the prostate, such as to the chest, abdomen or pelvis.

• #92 Diagnosis and Stages of Prostate Cancer – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/cancer/prostate-cancer/diagnosis-and-stages

  After receiving a diagnosis of prostate cancer, our team will try to determine your stage of cancer. The stage of cancer describes how much and far the cancer has spread in your body. It is one of the most important things to know when deciding how to best treat your cancer, including whether your cancer can be removed (resected) with surgery. You may need additional diagnostic tests to help our team formally assign a stage to your cancer, which is dependent upon the size and spread of the cancer. […] The Gleason Grading System is commonly used to determine the aggressiveness of prostate cancer, ranging from least to most aggressive with a score from 210. A higher number, such as 10, means a more advanced cancer. […] After your healthcare team identifies your stage of prostate cancer, they may also want to use any of the following post-diagnostic tests to learn more about your cancer: Computed tomography (CT or CAT) scan, a test which uses a combination of X-rays and software to create images of your prostate and nearby organs. It will help to discover if your cancer has spread into lymph nodes or other organs, Prostate-specific membrane antigen (PSMA) PET scan is an imaging test where radioactive tracers attach to PSMA, a protein found on most prostate cancer cells. This scan is especially helpful to determine if or where your prostate cancer has spread, Magnetic resonance imaging (MRI), a test which uses magnets and radio waves to create detailed images of your prostate and nearby organs and tissues. […] Lymph node biopsy, a test that examines if your prostate cancer has spread to nearby lymph nodes; small pieces of tissue are tested under a microscope.

• #93 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  Prostate cancer is the most common noncutaneous cancer in men, making the diagnosis and staging of this cancer of great medical and public interest. […] Screening for prostate cancer, with prostate-specific antigen (PSA) evaluation and sometimes digital rectal examination (DRE), can detect asymptomatic cases and allow early diagnosis. […] The American Cancer Society (ACS), the American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) have issued guidelines that differ on specific points but agree on the value of prostate cancer screening in selected populations, for patients who agree to screening after a discussion of the risks and benefits. […] Men with PSA levels above 10 ng/mL, high-grade histology (Gleason score of 7), or physical findings suggesting stage T3 disease should probably undergo a staging CT scan and bone scan.

• #94 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  The NCCN advises that, although very few men over the age of 75 benefit from PSA testing, a clinically significant number may develop aggressive cancers that pose significant risk if they are not detected before they produce symptoms. […] In men with PSA levels above 10 ng/mL, high-grade histology (Gleason score of 7 or higher), or physical findings that suggest stage T3 disease should probably undergo a staging computed tomography (CT) scan and bone scan. […] The CT scan can be used to evaluate extension into the bladder and lymph nodes to help stage the patient’s cancer or to consider lymph node sampling prior to treatment. […] The American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging system for cancer are provided below.

• #95 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  Prostate cancer is the most common noncutaneous cancer in men, making the diagnosis and staging of this cancer of great medical and public interest. […] Screening for prostate cancer, with prostate-specific antigen (PSA) evaluation and sometimes digital rectal examination (DRE), can detect asymptomatic cases and allow early diagnosis. […] The American Cancer Society (ACS), the American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) have issued guidelines that differ on specific points but agree on the value of prostate cancer screening in selected populations, for patients who agree to screening after a discussion of the risks and benefits. […] Men with PSA levels above 10 ng/mL, high-grade histology (Gleason score of 7), or physical findings suggesting stage T3 disease should probably undergo a staging CT scan and bone scan.

• #96 Prostate Cancer Diagnosis and Staging: Practice Essentials, Overview, Relevant Anatomy

  https://emedicine.medscape.com/article/458011-overview

  The NCCN advises that, although very few men over the age of 75 benefit from PSA testing, a clinically significant number may develop aggressive cancers that pose significant risk if they are not detected before they produce symptoms. […] In men with PSA levels above 10 ng/mL, high-grade histology (Gleason score of 7 or higher), or physical findings that suggest stage T3 disease should probably undergo a staging computed tomography (CT) scan and bone scan. […] The CT scan can be used to evaluate extension into the bladder and lymph nodes to help stage the patient’s cancer or to consider lymph node sampling prior to treatment. […] The American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging system for cancer are provided below.

• #97 Prostate cancer

  https://www.cancervic.org.au/cancer-information/types-of-cancer/prostate_cancer/diagnosing_prostate_cancer.html

  The biopsy results will show the grade of the cancer. […] For many years, the Gleason scoring system has been used to grade the tissue taken during a biopsy. […] Based on the size and grade of the cancer, and your PSA level before the biopsy, localised (early) prostate cancer will be classified as low risk, intermediate risk, or high risk. […] Prostate cancer often grows slowly, and even the more aggressive cases of prostate cancer tend to grow more slowly than other types of cancer. […] Compared with other cancers, prostate cancer has one of the highest five-year survival rates if diagnosed early.

• #98 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Different risk calculators and nomograms that aggregate data were developed in an attempt to better estimate tumor stage and aggressiveness. […] The gold standard to diagnose PCa with an elevated PSA is the 12 core extended sextant TRUS, the TRUS-guided prostate needle biopsy. […] A recent meta-analysis demonstrated that MRI-targeted biopsy significantly increases the detection rate of clinically significant cancers and decreases the detection on indolent cancers. […] After a complete clinical workup, clinicians should classify patients according to different major classifications (D’Amico, EAU, NCCN).

• #99 Prostate cancer

  https://www.cancervic.org.au/cancer-information/types-of-cancer/prostate_cancer/diagnosing_prostate_cancer.html

  The biopsy results will show the grade of the cancer. […] For many years, the Gleason scoring system has been used to grade the tissue taken during a biopsy. […] Based on the size and grade of the cancer, and your PSA level before the biopsy, localised (early) prostate cancer will be classified as low risk, intermediate risk, or high risk. […] Prostate cancer often grows slowly, and even the more aggressive cases of prostate cancer tend to grow more slowly than other types of cancer. […] Compared with other cancers, prostate cancer has one of the highest five-year survival rates if diagnosed early.

• #100 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Different risk calculators and nomograms that aggregate data were developed in an attempt to better estimate tumor stage and aggressiveness. […] The gold standard to diagnose PCa with an elevated PSA is the 12 core extended sextant TRUS, the TRUS-guided prostate needle biopsy. […] A recent meta-analysis demonstrated that MRI-targeted biopsy significantly increases the detection rate of clinically significant cancers and decreases the detection on indolent cancers. […] After a complete clinical workup, clinicians should classify patients according to different major classifications (D’Amico, EAU, NCCN).

• #101 Diagnosis of prostate cancer

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6488713/

  Different risk calculators and nomograms that aggregate data were developed in an attempt to better estimate tumor stage and aggressiveness. […] The gold standard to diagnose PCa with an elevated PSA is the 12 core extended sextant TRUS, the TRUS-guided prostate needle biopsy. […] A recent meta-analysis demonstrated that MRI-targeted biopsy significantly increases the detection rate of clinically significant cancers and decreases the detection on indolent cancers. […] After a complete clinical workup, clinicians should classify patients according to different major classifications (D’Amico, EAU, NCCN).

• #102 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  The Gleason score is a number given by the pathologist who examines the cancerous tissue samples under a microscope. The Gleason score refers to how different the prostate cancer cells/glands appear in comparison to normal prostate cells/glands. […] Prostate cancer is also assigned a stage, based on how advanced the disease is. Both your Gleason score and stage are critical deciding factors in what types of prostate cancer treatment may be recommended.

• #103 Tests for Prostate Cancer | Prostate Cancer Diagnosis | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html

  Doctors recommend that some men with prostate cancer consider genetic counseling and testing to look for certain inherited gene changes. […] Imaging tests use x-rays, magnetic fields, sound waves, or radioactive substances to create pictures of the inside of your body. […] A lymph node biopsy is rarely done as a separate procedure. It’s sometimes used when a radical prostatectomy isn’t planned, but when it’s still important to know if the lymph nodes contain cancer.

• #104 Prostate Cancer Diagnosis and Treatment | Knight Cancer Institute | OHSU

  https://www.ohsu.edu/knight-cancer-institute/prostate-cancer-diagnosis-and-treatment

  A prostatectomy is surgery to remove some or all of your prostate gland. It is most helpful when the cancer is confined to the prostate. […] Radiation therapy uses targeted beams of energy to kill cancer cells. […] Hormones in the body called androgens help prostate cancer cells grow. […] Chemotherapy uses medications to stop cancer cells from growing or reproducing. […] Genetic counseling and testing may help identify the best treatment for you. […] Our Prostate Cancer Genetics Clinic provides complete care for patients who have prostate cancer or have a genetic change that puts them at higher risk of prostate cancer. […] We follow guidelines of the National Comprehensive Cancer Network. It recommends germline genetic testing if you have prostate cancer and any of the following: Your prostate cancer is only in your prostate and high-risk; or your prostate cancer has spread to another part of your body. […] Talk with your care team about whether genetic counseling and testing is right for you.

• #105 Prostate Cancer Diagnosis and Treatment | Knight Cancer Institute | OHSU

  https://www.ohsu.edu/knight-cancer-institute/prostate-cancer-diagnosis-and-treatment

  A prostatectomy is surgery to remove some or all of your prostate gland. It is most helpful when the cancer is confined to the prostate. […] Radiation therapy uses targeted beams of energy to kill cancer cells. […] Hormones in the body called androgens help prostate cancer cells grow. […] Chemotherapy uses medications to stop cancer cells from growing or reproducing. […] Genetic counseling and testing may help identify the best treatment for you. […] Our Prostate Cancer Genetics Clinic provides complete care for patients who have prostate cancer or have a genetic change that puts them at higher risk of prostate cancer. […] We follow guidelines of the National Comprehensive Cancer Network. It recommends germline genetic testing if you have prostate cancer and any of the following: Your prostate cancer is only in your prostate and high-risk; or your prostate cancer has spread to another part of your body. […] Talk with your care team about whether genetic counseling and testing is right for you.

• #106 Prostate Cancer Diagnosis | Roswell Park Comprehensive Cancer Center – Buffalo, NY

  https://www.roswellpark.org/cancer/prostate/diagnosis

  Imaging tests. Other scans such as prostate specific membrane antigen positron emission tomography (PSMA PET/CT) can provide detailed images of the inside of your body to learn whether cancer may be found in other body areas such as lymph nodes, bones or other organs. […] Biopsy. A biopsy is a procedure that takes a sample of tissue or cells from the prostate to be examined in a laboratory to determine if cancer is present, and other characteristics that help guide treatment decisions. […] Genetic tests. These tests examine a sample of your blood to analyze your DNA and learn whether your prostate cancer might be caused by a certain gene mutation. The results of genetic testing can help guide decisions about increased surveillance for other related cancer types (breast, ovarian, colorectal, uterine and pancreatic) and well screening recommendations for your family members.

• #107 Prostate Cancer Diagnosis and Treatment | Knight Cancer Institute | OHSU

  https://www.ohsu.edu/knight-cancer-institute/prostate-cancer-diagnosis-and-treatment

  A prostatectomy is surgery to remove some or all of your prostate gland. It is most helpful when the cancer is confined to the prostate. […] Radiation therapy uses targeted beams of energy to kill cancer cells. […] Hormones in the body called androgens help prostate cancer cells grow. […] Chemotherapy uses medications to stop cancer cells from growing or reproducing. […] Genetic counseling and testing may help identify the best treatment for you. […] Our Prostate Cancer Genetics Clinic provides complete care for patients who have prostate cancer or have a genetic change that puts them at higher risk of prostate cancer. […] We follow guidelines of the National Comprehensive Cancer Network. It recommends germline genetic testing if you have prostate cancer and any of the following: Your prostate cancer is only in your prostate and high-risk; or your prostate cancer has spread to another part of your body. […] Talk with your care team about whether genetic counseling and testing is right for you.

• #108 Prostate Cancer Diagnosis | Roswell Park Comprehensive Cancer Center – Buffalo, NY

  https://www.roswellpark.org/cancer/prostate/diagnosis

  Imaging tests. Other scans such as prostate specific membrane antigen positron emission tomography (PSMA PET/CT) can provide detailed images of the inside of your body to learn whether cancer may be found in other body areas such as lymph nodes, bones or other organs. […] Biopsy. A biopsy is a procedure that takes a sample of tissue or cells from the prostate to be examined in a laboratory to determine if cancer is present, and other characteristics that help guide treatment decisions. […] Genetic tests. These tests examine a sample of your blood to analyze your DNA and learn whether your prostate cancer might be caused by a certain gene mutation. The results of genetic testing can help guide decisions about increased surveillance for other related cancer types (breast, ovarian, colorectal, uterine and pancreatic) and well screening recommendations for your family members.

• #109 Prostate Cancer Diagnosis | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/prostate/diagnosis

  ConfirmMDx is a test done on prostate biopsy samples that did not show cancer. It can help us decide whether to repeat a biopsy. […] Several genetic tests are used on prostate biopsy tissues, including Prolaris and Oncotype DX GPS. These tests can give you and your doctor more information by measuring how aggressive the cancer is.

• #110 Prostate Cancer Tests for Diagnosis & Screening

  https://www.cancercenter.com/cancer-types/prostate-cancer/diagnosis-and-detection

  Gleason scores range from 2 to 10, going from least to most aggressive prostate cancers. […] After a biopsy, the patients tissue sample is sent to a laboratory, where a specialized doctor called a pathologist studies it under a microscope. […] The pathologist is looking to see whether the cells are cancerous. […] Prostate biopsies sometimes return false-negative results. […] Your care team is aware that false-negatives occur and may consider a negative biopsy result in the context of other tests. […] Below are imaging tests that may be used to determine the type, stage and progression of a patients prostate cancer. […] The most common lab test for prostate cancer is advanced genomic testing, which examines a tumor to look for DNA alterations that may be driving the growth of the cancer.

• #111 Prostate Cancer Diagnosis | Roswell Park Comprehensive Cancer Center – Buffalo, NY

  https://www.roswellpark.org/cancer/prostate/diagnosis

  Molecular tumor tests. These advanced tests analyze cells from your biopsy to look at its molecular components and can help distinguish a low-risk cancer from a high-risk one. […] The most common prostate biopsy is a core needle biopsy. […] If you had a suspicious prostate MRI, using a special machine, Roswell Park can fuse the MRI image with a real-time ultrasound image, to localize the abnormal area on the ultrasound. We can then target this specific area of concern. Fusion or targeted biopsy improves the detection of clinically significant prostate cancer.

• #112 Biomarkers for Prostate Cancer: From Diagnosis to Treatment

  https://www.mdpi.com/2075-4418/13/21/3350

  Prostate cancer (PCa) is a widespread malignancy with global significance, which substantially affects cancer-related mortality. Its spectrum varies widely, from slow-progressing cases to aggressive or even lethal forms. Effective patient stratification into risk groups is crucial to therapeutic decisions and clinical trials. This review examines a wide range of diagnostic and prognostic biomarkers, several of which are integrated into clinical guidelines, such as the PHI, the 4K score, PCA3, Decipher, and Prolaris. […] The diagnosis relies on methods such as a digital rectal examination (DRE), a prostate-specific antigen (PSA) assessment, imaging, and a tissue biopsy with Gleason grading. […] The current diagnostic methods for PCa have various limitations that can lead to overdiagnoses and overtreatment. For example, PSA testing, while aiding early detection, lacks precision (20–40% accuracy), as non-malignant conditions can cause PSA elevation, potentially resulting in false positives.

• #113 Biomarkers for Prostate Cancer: From Diagnosis to Treatment

  https://www.mdpi.com/2075-4418/13/21/3350

  To address these issues, a biopsy may be suggested when two abnormal PSA levels or a palpable abnormality are present. […] In recent years, the growing understanding of the malignant biological characteristics of PCa and its molecular attributes has enabled the discovery of multiple biomarkers, which have been integrated with current diagnostic methods, risk assessments, and treatment selections. […] The specificity of using PSA as a screening tool for PCa has its limitations, especially when the PSA levels are lower than 10 µg/L. This lack of specificity results in a substantial proportion of men undergoing biopsies, either to confirm or rule out a malignancy, unnecessarily. […] To improve precision and decrease the occurrence of unnecessary or repeated biopsies, various supplementary tests such as the PHI, the 4K score, and PCA3 have been proposed.

• #114 Biomarkers for Prostate Cancer: From Diagnosis to Treatment

  https://www.mdpi.com/2075-4418/13/21/3350

  Prostate cancer (PCa) is a widespread malignancy with global significance, which substantially affects cancer-related mortality. Its spectrum varies widely, from slow-progressing cases to aggressive or even lethal forms. Effective patient stratification into risk groups is crucial to therapeutic decisions and clinical trials. This review examines a wide range of diagnostic and prognostic biomarkers, several of which are integrated into clinical guidelines, such as the PHI, the 4K score, PCA3, Decipher, and Prolaris. […] The diagnosis relies on methods such as a digital rectal examination (DRE), a prostate-specific antigen (PSA) assessment, imaging, and a tissue biopsy with Gleason grading. […] The current diagnostic methods for PCa have various limitations that can lead to overdiagnoses and overtreatment. For example, PSA testing, while aiding early detection, lacks precision (20–40% accuracy), as non-malignant conditions can cause PSA elevation, potentially resulting in false positives.

• #115

  https://www.nhs.uk/conditions/prostate-cancer/diagnosis/

  If you have a raised PSA level, your doctor may refer you to hospital for an MRI scan of your prostate. If the scan shows a problem, it can be targeted later with a biopsy. […] A biopsy may also be taken during a cystoscopy examination. […] Although a biopsy is more reliable than a PSA test, there can still be issues, such as: missing the cancer doctors can see the prostate using the ultrasound scan but might not always spot a tumour, needing another biopsy if your symptoms persist or your PSA level continues to rise you may be offered another MRI scan first, finding small, low-risk cancers that do not need treatment but may cause you anxiety and there is a possible related risk that you choose to undergo surgery or radiotherapy of little to no benefit that cause side effects, such as incontinence and erectile dysfunction (impotence).

• #116 Prostate Cancer Screening (PDQ®) – NCI

  https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq

  Prophylactic antibiotics, especially fluoroquinolones, are often used before transrectal needle biopsies. There are reports of increasing rates of sepsis, particularly with fluoroquinolone-resistant Escherichia coli, and hospitalization after the procedure. Therefore, men who undergo transrectal biopsy should be told to seek medical attention immediately if they experience fever after biopsy.

• #117 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  Diagnosis of prostate cancer is a four-step process. If the PSA levels in your blood test suggest the possibility that you may have prostate cancer, your physician will order a biopsy. If there is cancer present in the biopsy samples, it will be given a Gleason score and stage-two numbers that indicate the extent and aggressiveness of the cancer. […] Your prostate cancer screening includes a test to measure the levels of prostate-specific antigen (PSA) in your blood. Elevated PSA levels are often an early indication of prostate cancer as well as other prostate disorders. […] While the PSA test helps assess the risk of prostate cancer, the prostate biopsy is the only way to make an accurate diagnosis. If either your digital rectal exam or blood test had an abnormal result, your physician will often order a biopsy.

• #118 Prostate Cancer Diagnosis | NYU Langone Health

  https://nyulangone.org/conditions/prostate-cancer/diagnosis

  If screening tests reveal abnormal results, your urologist discusses the risks and benefits of additional testing with you based on your age, risk factors, and symptoms. […] Your doctor may then perform the following tests to check for the presence of prostate cancer and to assess whether the cancer is growing slowly or may require more immediate treatment. […] In a prostate-specific antigen, or PSA, test, a small amount of blood is drawn and sent to a laboratory for analysis. This is the same test that is used to screen for prostate cancer. […] If your PSA is elevated but the risk of aggressive prostate cancer is low, your doctor may perform a type of blood test that measure prostate cancer biomarkers to determine whether a biopsy is necessary. […] If your doctor feels a prostate irregularity during the digital rectal exam, or if more than one PSA test result indicates elevated levels of the protein in the blood, your doctor may recommend an MRI scan of the prostate.

• #119 Prostate Cancer Diagnosis | NYU Langone Health

  https://nyulangone.org/conditions/prostate-cancer/diagnosis

  If screening tests reveal abnormal results, your urologist discusses the risks and benefits of additional testing with you based on your age, risk factors, and symptoms. […] Your doctor may then perform the following tests to check for the presence of prostate cancer and to assess whether the cancer is growing slowly or may require more immediate treatment. […] In a prostate-specific antigen, or PSA, test, a small amount of blood is drawn and sent to a laboratory for analysis. This is the same test that is used to screen for prostate cancer. […] If your PSA is elevated but the risk of aggressive prostate cancer is low, your doctor may perform a type of blood test that measure prostate cancer biomarkers to determine whether a biopsy is necessary. […] If your doctor feels a prostate irregularity during the digital rectal exam, or if more than one PSA test result indicates elevated levels of the protein in the blood, your doctor may recommend an MRI scan of the prostate.

• #120 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  Diagnosis of prostate cancer is a four-step process. If the PSA levels in your blood test suggest the possibility that you may have prostate cancer, your physician will order a biopsy. If there is cancer present in the biopsy samples, it will be given a Gleason score and stage-two numbers that indicate the extent and aggressiveness of the cancer. […] Your prostate cancer screening includes a test to measure the levels of prostate-specific antigen (PSA) in your blood. Elevated PSA levels are often an early indication of prostate cancer as well as other prostate disorders. […] While the PSA test helps assess the risk of prostate cancer, the prostate biopsy is the only way to make an accurate diagnosis. If either your digital rectal exam or blood test had an abnormal result, your physician will often order a biopsy.

• #121 How We Diagnose Prostate Cancer | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/prostate-cancer/diagnosis

  Beginning with your first appointment at the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center, you will be matched with specialists and researchers who study genitourinary cancers exclusively. […] Finding the right pathologists and radiologists to manage your prostate cancer diagnosis is key to developing a successful treatment plan. Our radiology and pathology teams are devoted to prostate cancer, evaluating over 2,200 cases each year. […] As men age, the risk of developing prostate cancer increases. Many men will develop prostate cancer, but not all develop a harmful form of the disease. That’s why it’s important to be tested and treated as early as possible. Early diagnosis can improve your chances for successful treatment and recovery. […] These tests are most commonly used to diagnose prostate cancer:

• #122 Diagnosis – Prostate cancer – Cancer Institute | Northwell Health

  https://cancer.northwell.edu/care-care/prostate-cancer/diagnosis

  DIAGNOSING PROSTATE CANCER We offer leading-edge diagnostic technology and procedures for prostate cancer, so you can be sure of an accurate diagnosis and the best possible outcome. […] Our team of nationally acclaimed urologic oncologists works with our radiologists and pathologists to arrive at an accurate, timely diagnosis. Northwell was one of the first institutions to develop (in conjunction with the National Cancer Institute) and implement the UroNav biopsy method a system that fuses MRI and ultrasound imagery together in real time, during the biopsy to allow for highly precise biopsies with a much lower infection risk. It also helps make nerve-sparing surgery possible by precisely locating the tumor that needs to be removed. […] Advanced diagnostic tests and procedures we offer include: Prostate magnetic resonance imaging (MRI): A prostate MRI uses a magnetic field, radiofrequency pulses and a computer to produce detailed pictures of the prostate. It provides more precise and detailed images than any other imaging method and allows us a complete, 100% view of the prostate.

• #123 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  Diagnosis of prostate cancer is a four-step process. If the PSA levels in your blood test suggest the possibility that you may have prostate cancer, your physician will order a biopsy. If there is cancer present in the biopsy samples, it will be given a Gleason score and stage-two numbers that indicate the extent and aggressiveness of the cancer. […] Your prostate cancer screening includes a test to measure the levels of prostate-specific antigen (PSA) in your blood. Elevated PSA levels are often an early indication of prostate cancer as well as other prostate disorders. […] While the PSA test helps assess the risk of prostate cancer, the prostate biopsy is the only way to make an accurate diagnosis. If either your digital rectal exam or blood test had an abnormal result, your physician will often order a biopsy.

• #124 Diagnosis – Prostate cancer – Cancer Institute | Northwell Health

  https://cancer.northwell.edu/care-care/prostate-cancer/diagnosis

  Many men come to us for a diagnosis after getting an elevated prostate specific antigen (PSA) blood test, or after their doctor has found a prostate nodule. We know it can be a time of heightened anxiety and stress, so we developed the Rapid Diagnostic Pathway (RDP) to help you get answers as quickly as possible. […] A clear, fast path to an accurate diagnosis. At Northwell, one call is all it takes to get the care you need. We’ve created a clear pathway to help you understand the cause behind your elevated PSA result or prostate nodule. In just a couple of weeks, you’ll have a diagnosis and the information you need to make an informed decision about your next steps. […] Same-day or next-day appointments. You won’t have to wait for weeks to see a specialist. At Northwell, you can speak with a specially trained nurse practitioner and get your care coordinated right away. You can even connect with our expert clinicians via video call, who will review your medical history and symptoms all from the comfort of your home.

• #125 How is Prostate Cancer Diagnosed? | Prostate Cancer Diagnosis

  https://www.unitedurology.com/conditions-treatments/for-men/prostate-cancer/how-is-prostate-cancer-diagnosed-/

  Diagnosis of prostate cancer is a four-step process. If the PSA levels in your blood test suggest the possibility that you may have prostate cancer, your physician will order a biopsy. If there is cancer present in the biopsy samples, it will be given a Gleason score and stage-two numbers that indicate the extent and aggressiveness of the cancer. […] Your prostate cancer screening includes a test to measure the levels of prostate-specific antigen (PSA) in your blood. Elevated PSA levels are often an early indication of prostate cancer as well as other prostate disorders. […] While the PSA test helps assess the risk of prostate cancer, the prostate biopsy is the only way to make an accurate diagnosis. If either your digital rectal exam or blood test had an abnormal result, your physician will often order a biopsy.

• #126 Diagnosis – Prostate cancer – Cancer Institute | Northwell Health

  https://cancer.northwell.edu/care-care/prostate-cancer/diagnosis

  Many men come to us for a diagnosis after getting an elevated prostate specific antigen (PSA) blood test, or after their doctor has found a prostate nodule. We know it can be a time of heightened anxiety and stress, so we developed the Rapid Diagnostic Pathway (RDP) to help you get answers as quickly as possible. […] A clear, fast path to an accurate diagnosis. At Northwell, one call is all it takes to get the care you need. We’ve created a clear pathway to help you understand the cause behind your elevated PSA result or prostate nodule. In just a couple of weeks, you’ll have a diagnosis and the information you need to make an informed decision about your next steps. […] Same-day or next-day appointments. You won’t have to wait for weeks to see a specialist. At Northwell, you can speak with a specially trained nurse practitioner and get your care coordinated right away. You can even connect with our expert clinicians via video call, who will review your medical history and symptoms all from the comfort of your home.

• #127 Diagnosis – Prostate cancer – Cancer Institute | Northwell Health

  https://cancer.northwell.edu/care-care/prostate-cancer/diagnosis

  To determine your exact condition, our expert clinicians may suggest more diagnostic tests like an MRI, a biopsy, or another PSA. Our team will coordinate everything getting your medical records from other physicians, planning for any tests you may need, scheduling a consultation to review your results with a urologist, and sending updates to your referring physician. […] If your results are negative for cancer, we’ll make a follow-up plan to monitor your PSA levels. If you have a prostate cancer diagnosis, you’ll get seamless access to our specialized team of radiologists, pathologists, urologists, radiation oncologists and medical oncologists. […] Previously, when a patient had an elevated PSA, it would take 8-10 weeks to complete the workup. RDP creates a smooth and seamless experience. Patients can be seen the same day after being referred to our group of prostate cancer experts.

• #128 Diagnosis – Prostate cancer – Cancer Institute | Northwell Health

  https://cancer.northwell.edu/care-care/prostate-cancer/diagnosis

  To determine your exact condition, our expert clinicians may suggest more diagnostic tests like an MRI, a biopsy, or another PSA. Our team will coordinate everything getting your medical records from other physicians, planning for any tests you may need, scheduling a consultation to review your results with a urologist, and sending updates to your referring physician. […] If your results are negative for cancer, we’ll make a follow-up plan to monitor your PSA levels. If you have a prostate cancer diagnosis, you’ll get seamless access to our specialized team of radiologists, pathologists, urologists, radiation oncologists and medical oncologists. […] Previously, when a patient had an elevated PSA, it would take 8-10 weeks to complete the workup. RDP creates a smooth and seamless experience. Patients can be seen the same day after being referred to our group of prostate cancer experts.

• #129

  https://www.siemens-healthineers.com/perspectives/prostate-cancer

  Prostate cancer remains a uniquely challenging and complex illness, with significant complications and unpredictable treatment outcomes. Despite the advances made in recent years, it remains the fifth leading cause of death worldwide and the second most frequent cancer diagnosis in men. […] Prostate cancer is most commonly diagnosed in men aged 65 or older, with about 6 in 10 cases occurring in this age group, and it is rare in men under 40. […] Diagnoses are projected to increase from 1.4 million a year in 2020 to 2.9 million by 2040. […] Regular testing for prostate cancer can help detect the disease early when it is most treatable. […] The PSA test is indicated for the measurement of total PSA (both free and complexed PSA) in conjunction with Digital Rectal Exam (DRE) as an aid in the detection of prostate cancer in men aged 50 years and older.

• #130 Prostate cancer – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/diagnosis-treatment/drc-20353093

  Prostate cancer stages range from 1 to 4. A lower number means the cancer is small and only in the prostate. A lower number stage typically means the cancer is very likely to be cured. If the cancer grows larger or spreads, the stage goes up. A higher number stage may mean a cure is less likely. […] The chance of surviving prostate cancer is quite good for most people. To understand prostate cancer survival rates, experts study many people with prostate cancer to see how many are living five years after their diagnosis. […] When the cancer is only in the prostate, the chance of surviving at least five years is 100%. As the cancer spreads beyond the prostate, the chances get lower. When prostate cancer has spread to other parts of the body, called metastatic prostate cancer, the chances of surviving at least five years is about 37%.

• #131 Prostate Cancer Tests for Diagnosis & Screening

  https://www.cancercenter.com/cancer-types/prostate-cancer/diagnosis-and-detection

  Prostate cancer occurs when cells start growing out of control in the prostate. Its an important health issue for all men to be aware of, because prostate cancer is the most common cancer in men after skin cancers, according to the National Cancer Institute. […] Prostate cancer is typically treatable if caught early. More than 90 percent of prostate cancers are found when the disease is in the beginning stages, confined to the prostate and nearby organs. […] Unlike screenings for breast cancer and colon cancer, there are no universal screening guidelines for prostate cancer. The U.S. Preventive Services Task Force (USPSTF) recommends that men age 55 to 69 weigh the benefits and risks before deciding whether they should undergo screening, which is typically performed with a blood test that measures levels of a protein called prostate-specific antigen (PSA).

Zobacz więcej